NYSE:NVO • US6701002056
We assign a fundamental rating of 6 out of 10 to NVO. NVO was compared to 193 industry peers in the Pharmaceuticals industry. While NVO has a great profitability rating, there are some minor concerns on its financial health. NVO scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally NVO also has an excellent dividend rating.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROIC | 30.79% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.56 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.19 | ||
| Fwd PE | 10.29 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.01 | ||
| EV/EBITDA | 7.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.9% |
NYSE:NVO (3/2/2026, 9:43:10 AM)
37.09
-0.36 (-0.96%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.9% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.19 | ||
| Fwd PE | 10.29 | ||
| P/S | 3.38 | ||
| P/FCF | 36.01 | ||
| P/OCF | 8.76 | ||
| P/B | 5.38 | ||
| P/tB | 16.31 | ||
| EV/EBITDA | 7.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROCE | 39.01% | ||
| ROIC | 30.79% | ||
| ROICexc | 33.56% | ||
| ROICexgc | 59.2% | ||
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% | ||
| FCFM | 9.38% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 0.79 | ||
| Cap/Depr | 409.94% | ||
| Cap/Sales | 29.16% | ||
| Interest Coverage | 37.34 | ||
| Cash Conversion | 79.59% | ||
| Profit Quality | 28.3% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 3.56 |
ChartMill assigns a fundamental rating of 6 / 10 to NVO.
ChartMill assigns a valuation rating of 7 / 10 to NOVO-NORDISK A/S-SPONS ADR (NVO). This can be considered as Undervalued.
NOVO-NORDISK A/S-SPONS ADR (NVO) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 10.19 and the Price/Book (PB) ratio is 5.38.
The financial health rating of NOVO-NORDISK A/S-SPONS ADR (NVO) is 4 / 10.